Showing 1781-1790 of 3380 results for "".
Increasing Profitability by Delivering a Better Patient Payment Experience
https://practicaldermatology.com/topics/practice-management/increasing-profitability-by-delivering-a-better-patient-payment-experience/21081/Happy Patients, Happy Practice
https://practicaldermatology.com/topics/practice-management/happy-patients-happy-practice/21138/Six tips for effectively dealing with conflict.Employee Engagement
https://practicaldermatology.com/topics/practice-management/employee-engagement/21267/Promoting employee engagement is key to success in the workplace.Dermatology and the ICD-10 Code Conundrum
https://practicaldermatology.com/topics/practice-management/dermatology-and-the-icd-10-code-conundrum/21372/EHRs equipped for ICD-10 can make the impending transition smooth for any practice.Prescribing Pitfalls Part II: Techniques for Prescribing Success
https://practicaldermatology.com/topics/practice-management/prescribing-pitfalls-part-ii-techniques-for-prescribing-success/21413/Simple strategies employed in the office can improve the likelihood of treatment success and enhance patient satisfaction.New Products and Pharmacologic Advancements
https://practicaldermatology.com/columns/new-products/new-products-and-pharmacologic-advancements/21663/Non-genital Warts: A Review of Current Treatments
https://practicaldermatology.com/topics/general-topics/non-genital-warts-a-review-of-current-treatments/21884/When determining which treatment modality to choose for non-genital warts, there are several factors to consider, including the convenience of the treatment, patient discomfort, location of warts, and potential side effects.How to Integrate Physician-Dispensed Products
https://practicaldermatology.com/topics/general-topics/PD0609_10-php/22819/With the correct protocols, staff training, and product selection, physician dispensing can help retain your current patient base and assist in marketing to new patients.Upadacitinib and Cardiovascular Events in AD
https://practicaldermatology.com/issues/october-2025/upadacitinib-and-cardiovascular-events-in-ad/39755/A recent review examined whether upadacitinib, a selective Janus kinase 1 (JAK1) inhibitor approved for atopic dermatitis (AD) and other chronic inflammatory diseases, may—despite a boxed warning to the contrary—confer cardioprotective and thromboprotective effects.A Highly Effective Topical Compounded Medication for the Treatment of Cutaneous Warts
https://practicaldermatology.com/topics/general-topics/a-highly-effective-topical-compounded-medication-for-the-treatment-of-cutaneous-warts/20583/A compounded formulation with an adhesive vehicle shows promise for one of the most common and frustrating conditions to treat in dermatology.